Biofrontera (BFRI) Projected to Post Quarterly Earnings on Thursday

Biofrontera (NASDAQ:BFRI) is expected to be announcing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.1150) per share and revenue of $10.25 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 11:00 AM ET.

Biofrontera (NASDAQ:BFRI) last posted its earnings results on Thursday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.21. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $16.15 million. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. On average, analysts expect Biofrontera to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biofrontera Stock Down 9.0%

BFRI opened at $1.01 on Wednesday. The firm has a 50 day moving average price of $0.97 and a 200 day moving average price of $0.90. The company has a market cap of $12.13 million, a PE ratio of -0.98 and a beta of 0.89. Biofrontera has a 1 year low of $0.54 and a 1 year high of $1.19. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.40 and a current ratio of 1.52.

Institutional Trading of Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC raised its position in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.75.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.